Laura E. Niklason Sells 261,369 Shares of Humacyte, Inc. (NASDAQ:HUMA) Stock

Humacyte, Inc. (NASDAQ:HUMA) CEO Laura E. Niklason sold 261,369 shares of the company’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total transaction of $1,150,023.60. Following the completion of the transaction, the chief executive officer now directly owns 1,730,884 shares in the company, valued at approximately $7,615,889.60. The trade was a 13.12 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Humacyte Trading Down 0.7 %

NASDAQ HUMA opened at $4.38 on Friday. The company has a 50-day moving average price of $5.36 and a 200-day moving average price of $6.18. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61. Humacyte, Inc. has a 52 week low of $2.43 and a 52 week high of $9.97.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. nVerses Capital LLC bought a new stake in Humacyte during the second quarter valued at about $28,000. Concurrent Investment Advisors LLC bought a new position in shares of Humacyte during the 3rd quarter valued at about $75,000. Principal Financial Group Inc. purchased a new position in shares of Humacyte during the second quarter valued at about $83,000. FORA Capital LLC bought a new stake in shares of Humacyte in the third quarter worth about $96,000. Finally, Profund Advisors LLC purchased a new stake in shares of Humacyte in the second quarter worth about $97,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on HUMA. EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. Benchmark reissued a “buy” rating and set a $15.00 target price on shares of Humacyte in a research note on Thursday, October 10th. TD Cowen reiterated a “buy” rating and issued a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 target price on shares of Humacyte in a research report on Friday, September 20th. Finally, BTIG Research reissued a “buy” rating and issued a $10.00 price target on shares of Humacyte in a research note on Friday, October 18th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $11.00.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.